Stevanato Group, Swiss elastomer supplier Datwyler and U.S. wearable‑device developer LTS Device Technologies announced a joint venture to create a platform that will enable on‑body administration of subcutaneous therapies up to 20 mL, a volume that is becoming increasingly common in biologic treatments.
The platform will combine Datwyler’s NeoFlex™ plungers, LTS’s Sorrel™ wearable delivery system, and Stevanato’s EZ‑fill® large‑volume cartridges. The three companies will demonstrate the integrated solution at Pharmapack’s Learning Lab in Paris on January 21‑22, 2026.
The collaboration expands Stevanato beyond its core syringes and vials into the large‑volume biologic delivery market, which is projected to reach $483 billion by 2034. It also taps a patient preference trend, with 73 % of respondents favoring in‑home self‑administration, and positions the alliance against competitors such as West Pharmaceutical Services and Becton Dickinson.
Analysts reacted positively to the announcement; Morgan Stanley raised its price target for Stevanato to $26 from $24, reflecting confidence that the partnership will strengthen the company’s competitive stance and open new revenue streams.
By integrating complementary technologies, the alliance aims to reduce patient burden, improve safety, and streamline manufacturing for pharmaceutical customers. The partnership is expected to create new revenue opportunities for Stevanato as biologics continue to dominate the market and the demand for patient‑centric delivery solutions grows.
The collaboration signals a strategic pivot for Stevanato toward high‑growth biologic delivery, reinforcing its position in the rapidly expanding large‑volume subcutaneous segment and potentially reshaping its product mix and market reach.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.